Chandramouleswar Amara, MD
Child & Adolescent Psychiatry · Petersburg, VANPI 1942265509
Payments from drug & device makers
Across 643 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Sunovion Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$994
- Lundbeck LLC$951
- Alkermes, Inc.$858
- AbbVie$656
- plus $5K from 23 others
What the payments were for
- Food & beverage$10,14699%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 53 | $1,094 |
| Sunovion Pharmaceuticals Inc. | 88 | $1,029 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 83 | $994 |
| Lundbeck LLC | 57 | $951 |
| Alkermes, Inc. | 43 | $858 |
| AbbVie(2 entities) | 62 | $656 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $630 |
| Otsuka America Pharmaceutical, Inc. | 38 | $625 |
| Supernus Pharmaceuticals, Inc. | 40 | $611 |
| Neurocrine Biosciences, Inc. | 31 | $603 |
| Teva Pharmaceuticals USA, Inc. | 41 | $516 |
| E.r. Squibb & Sons, L.L.C. | 16 | $348 |
| Vanda Pharmaceuticals Inc. | 10 | $268 |
| Axsome Therapeutics, Inc. | 10 | $229 |
| Corium, LLC | 8 | $217 |
| Ironshore Pharmaceuticals Inc. | 7 | $129 |
| Collegium Pharmaceutical, Inc. | 5 | $80 |
| Almatica Pharma LLC | 4 | $71 |
| Shire North American Group Inc | 5 | $69 |
| Tris Pharma Inc | 3 | $67 |
| Stimwave Technologies Incorporated | 1 | $28 |
| Eisai Inc. | 1 | $24 |
| Brainsway USA Inc | 1 | $21 |
| Harmony Biosciences LLC | 1 | $21 |
| Biogen | 1 | $19 |
| Bausch Health US, LLC | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Indivior Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$129
How this compares
$10,220 in reported general payments places this provider in the 95th percentile of 115 child & adolescent psychiatry providers in Virginia.
See all child & adolescent psychiatry providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 62 | $203,741 |
| VraylarCariprazine Hcl | 41 | $64,109 |
| Abilify MaintenaAripiprazole | 19 | $60,689 |
| RexultiBrexpiprazole | 28 | $41,819 |
| Lurasidone Hcl | 96 | $21,693 |
| ZyprexaOlanzapine | 12 | $17,180 |
| Olanzapine | 197 | $9,917 |
| Oxcarbazepine | 126 | $7,590 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 183 | $7,031 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,861 |
| QuviviqDaridorexant Hcl | 12 | $6,093 |
| Aripiprazole | 99 | $5,676 |
| Alprazolam | 656 | $4,689 |
| Quetiapine Fumarate | 336 | $3,986 |
| Duloxetine Hcl | 253 | $3,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,094 | $203,74162 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $625 | $102,50747 claims |
| AbbVieVraylar | $656 | $64,10941 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $630 | $6,86114 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $17 | $6,09312 claims |
| Almatica Pharma LLCSertraline Hcl | $71 | $1,108205 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 115 child & adolescent psychiatry providers in Virginia.
Other child & adolescent psychiatry in Petersburg
- Thresa SimonPetersburg$1.8M
- Haluk AydinPetersburg$2K
- Devi VasuPetersburg$2K
- Mohammad MubbasharPetersburg$2K
- James WooldridgePetersburg$449
- Vishal MadaanCharlottesville$143K
- Charles HallRichmond$10K
- David GouldRichmond$9K
- Rakesh ShahHopewell$7K
- Vikas MangewalaFairfax$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.